Table 1.
Patient and transplant characteristics of patients with nonmalignant diseases
| Variable | N (%) |
|---|---|
| No. of patients | 4083 |
| Age, y | |
| 0-2 | 908 (22) |
| 2-10 | 1322 (32) |
| 10-20 | 965 (24) |
| >20 | 888 (22) |
| Median age (range) | 9 (<1-77) |
| Recipient sex | |
| Male | 2417 (59) |
| Female | 1666 (41) |
| Race | |
| White | 2811 (69) |
| African American | 791 (19) |
| Asian | 255 (6) |
| Pacific islander | 14 (<1) |
| Native American | 51 (1) |
| Missing | 161 (4) |
| Recipient CMV status | |
| Negative | 1708 (42) |
| Positive | 2291 (56) |
| Missing | 84 (2) |
| Performance status (Lansky <18 y, Karnofsky >18 y) | |
| 90-100 | 3210 (79) |
| <90 | 776 (19) |
| Missing | 97 (2) |
| HCT-CI | |
| 0 | 2512 (62) |
| 1-2 | 821 (20) |
| 3-4 | 556 (14) |
| >5 | 194 (5) |
| Regroup disease categorization | |
| Aplastic anemia | 1337 (33) |
| BM failure | 470 (12) |
| Hemoglobinopathies | 656 (16) |
| Immune deficiency | 796 (19) |
| Metabolic disease | 371 (9) |
| Histiocytic disorders | 432 (11) |
| Autoimmune disease | 21 (<1) |
| Transplant-related variables | |
| Donor and graft | |
| 8/8 Matched related donor BM | 1118 (27) |
| 8/8 Matched related donor PBSC | 133 (3) |
| ≤7/8 Related donor BM | 135 (3) |
| ≤7/8 Related donor PBSC | 118 (3) |
| 8/8 Unrelated donor BM | 922 (23) |
| 8/8 Unrelated donor PBSC | 225 (6) |
| 7/8 Unrelated donor BM | 282 (7) |
| 7/8 Unrelated donor PBSC | 90 (2) |
| ≤6/8 Unrelated donor BM or PBSC | 102 (2) |
| 6/6 Cord | 163 (4) |
| 5/6 Cord | 282 (7) |
| ≤4/6 Cord | 450 (11) |
| Missing HLA-match | 63 (2) |
| Donor sex | |
| Male | 1854 (45) |
| Female | 1330 (33) |
| Cord blood | 895 (22) |
| Missing | 4 (<1) |
| Conditioning intensity* | |
| Myeloablative | 1439 (35) |
| Bu/Cy based | 1000 |
| Bu/Flu based | 342 |
| TBI based | 51 |
| Others | 46 |
| Reduced intensity | 1820 (45) |
| Flu/Mel based | 911 |
| Flu/Cy + others | 479 |
| Bu/Flu based | 104 |
| Cy/TBI based | 154 |
| Others | 172 |
| Immunosuppressive | 759 (19) |
| Cy | 444 |
| Flu/Cy | 263 |
| Others | 52 |
| None planned | 65 (2) |
| GVHD prophylaxis† | |
| Calcineurin inhibitor ± others (not MTX, MMF) | 719 (18) |
| Calcineurin inhibitor + methotrexate based | 1725 (42) |
| Calcineurin inhibitor + MMF (not MTX) based | 1205 (30) |
| T-cell depletion ± other | 287 (7) |
| Others | 120 (3) |
| None | 25 (<1) |
| Missing | 2 (<1) |
| In vivo T-cell depletion | |
| ATG | 2240 (55) |
| Campath | 1259 (31) |
| None | 584 (14) |
| HCT year | |
| 2007 | 38 (<1) |
| 2008 | 451 (11) |
| 2009 | 573 (14) |
| 2010 | 528 (13) |
| 2011 | 612 (15) |
| 2012 | 603 (15) |
| 2013 | 669 (16) |
| 2014 | 609 (15) |
Bu, busulfan; CNI, calcineurin inhibitor; Cy, cyclophosphamide; Flu, fludarabine; Mel, melphalan; MMF, mycophenolate mofetil; MTX, methotrexate; TBI, total body irradiation.
*
See supplemental Table 1 for conditioning regimens.
†
See supplemental Table 2 for GVHD prophylaxis regimens.